Facebook
Twitter
LinkedIn
Forward
12th Annual Advances in Hematology & Oncology Fall Symposium
The practice of clinical hematology and oncology has been rapidly changing in recent years. Diseases and conditions that previously were extraordinarily difficult to manage have seen new treatment options emerge that have significantly improved clinical outcomes.
This symposium will update participants on lymphoma, neurological oncology, advanced skin cancers, musculoskeletal intervention, the latest clinical trials and more.
Target Audience
Physicians, Physician Assistants, Nurse Practitioners, Pharmacists, Registered Nurses
Learning Objectives
Participants who engage in this educational activity will be able to:
- Identify current evidence-based practice guidelines for topic areas presented
- Identify currently-available clinical trials for potential enrollment, to benefit their patients
- Contribute to recommendations for incorporation of techniques to increase access to quality care and increase enrollment in cancer clinical trials
7:00 – 8:00 a.m. Check-in/View Exhibits/Breakfast
8:00 – 8:40 a.m. Oncodermatology Updates - Kassandra Holzem, MD
8:40 – 9:20 a.m. What's New in Lymphoma in 2023 - Brad Kahl, MD
9:20 – 10:00 a.m. Advances in Neurosurgical Oncology – Max Krucoff, MD
10:00 – 10:15 a.m. Break
10:15 – 10:55 a.m. Breakout Sessions
- Advanced IR Palliative & MSK Interventions - Brandon Key, MD
- Hot Clinical Trials - John Burfeind, MD
10:55 – 11:35 a.m. Surgical Management of Breast Cancer - Caitlin Patten, MD
11:35 – 12:15 p.m. Melanoma: Raising the Bar - Sunandana Chandra, MD
12:15 p.m. Lunch/Adjourn
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
The following persons in control of content disclosed the following financial relationships which were reviewed via the MCW conflict of interest mitigation process and addressed.
| Name | Company | Role |
|---|---|---|
| Brad Kahl, MD | ||
| Sunandana Chandra, MD | Pfizer, Regeneron, Bristol Myers Squibb, and Novartis | Advisory Committee |
|
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 4 hours of participation for continuing education for allied health professionals.
Available Credit
- 4.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 4.00 Hours of ParticipationHours of Participation credit.